Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Denali Therapeutics Inc (NASDAQ: DNLI) was $13.95 for the day, up 3.87% from the previous closing price of $13.43. In other words, the price has increased by $3.87 from its previous closing price. On the day, 2.33 million shares were traded. DNLI stock price reached its highest trading level at $14.06 during the session, while it also had its lowest trading level at $13.3.
Ratios:
Our analysis of DNLI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 10.27 and its Current Ratio is at 10.27. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $31.Deutsche Bank initiated its Buy rating on February 11, 2025, with a $31 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 12 ’25 when Schuth Alexander O. sold 2,937 shares for $13.58 per share. The transaction valued at 39,884 led to the insider holds 242,346 shares of the business.
Ho Carole sold 2,937 shares of DNLI for $39,884 on Aug 12 ’25. The Chief Medical Officer now owns 217,391 shares after completing the transaction at $13.58 per share. On Aug 13 ’25, another insider, Ho Carole, who serves as the Chief Medical Officer of the company, sold 806 shares for $14.64 each. As a result, the insider received 11,800 and left with 216,585 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNLI now has a Market Capitalization of 2039661184 and an Enterprise Value of 1188682240.
Stock Price History:
The Beta on a monthly basis for DNLI is 1.30, which has changed by -0.52111226 over the last 52 weeks, in comparison to a change of 0.1529237 over the same period for the S&P500. Over the past 52 weeks, DNLI has reached a high of $33.33, while it has fallen to a 52-week low of $10.57. The 50-Day Moving Average of the stock is -2.49%, while the 200-Day Moving Average is calculated to be -14.62%.
Shares Statistics:
DNLI traded an average of 1.90M shares per day over the past three months and 2492760 shares per day over the past ten days. A total of 145.69M shares are outstanding, with a floating share count of 130.83M. Insiders hold about 10.52% of the company’s shares, while institutions hold 94.44% stake in the company. Shares short for DNLI as of 1757894400 were 13079532 with a Short Ratio of 6.90, compared to 1755216000 on 13471070. Therefore, it implies a Short% of Shares Outstanding of 13079532 and a Short% of Float of 10.01.
Earnings Estimates
The performance of Denali Therapeutics Inc (DNLI) in the stock market is under the watchful eye of 15.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.38 and low estimates of -$0.95.
Analysts are recommending an EPS of between -$2.64 and -$3.3 for the fiscal current year, implying an average EPS of -$3.01. EPS for the following year is -$2.82, with 14.0 analysts recommending between -$1.81 and -$3.68.
